The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe.
Health-related quality of life
Socioeconomic burden
Ulcerative colitis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
04 Dec 2021
04 Dec 2021
Historique:
received:
21
08
2020
accepted:
15
11
2021
entrez:
5
12
2021
pubmed:
6
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Ulcerative colitis (UC) is an inflammatory bowel disease with increasing prevalence worldwide. Current treatment strategies place considerable economic and humanistic burdens on patients. The aim of this study was to determine the socioeconomic burden of UC in adult patients in European countries in a real-world setting. In this retrospective, cross-sectional and observational pan-European study, patients with moderate or severe UC were assigned to ARM 1 and patients who had moderate or severe UC but achieved mild or remission status 12 months before index date (or clinical consultation date), were assigned to ARM 2. Clinical and medical resource use data were collected via electronic case report forms, and data on non-medical and indirect costs, and health-related quality of life (HRQoL) were collected via patient and public involvement and engagement (PPIE) questionnaires. Per-patient annual total costs per ARM and per country were calculated using the collated resource use in the last 12 months (between the start of the documentation period and patient consultation or index date) and country specific unit costs. Quality of life was described by arm and by country. In the physician-reported eCRF population (n = 2966), the mean annual direct medical cost was €4065 in ARM 1 (n = 1835) and €2935 in ARM 2 (n = 1131). In the PPIE population (ARM 1, n = 1001; ARM 2, n = 647), mean annual direct cost was €4526 in ARM 1 and €3057 in ARM 2, mean annual direct non-medical cost was €1162 in ARM 1 and €1002 in ARM 2, mean annual indirect cost was €3098 in ARM 1 and €2309 ARM 2, and mean annual total cost was in €8787 in ARM 1 and €6368 in ARM 2. HRQoL scores showed moderate to high burden of UC in both groups. The cost and HRQoL burden were high in patients in both ARM 1 and ARM 2 indicating unmet needs in the UC active population.
Sections du résumé
BACKGROUND
BACKGROUND
Ulcerative colitis (UC) is an inflammatory bowel disease with increasing prevalence worldwide. Current treatment strategies place considerable economic and humanistic burdens on patients. The aim of this study was to determine the socioeconomic burden of UC in adult patients in European countries in a real-world setting.
METHODS
METHODS
In this retrospective, cross-sectional and observational pan-European study, patients with moderate or severe UC were assigned to ARM 1 and patients who had moderate or severe UC but achieved mild or remission status 12 months before index date (or clinical consultation date), were assigned to ARM 2. Clinical and medical resource use data were collected via electronic case report forms, and data on non-medical and indirect costs, and health-related quality of life (HRQoL) were collected via patient and public involvement and engagement (PPIE) questionnaires. Per-patient annual total costs per ARM and per country were calculated using the collated resource use in the last 12 months (between the start of the documentation period and patient consultation or index date) and country specific unit costs. Quality of life was described by arm and by country.
RESULTS
RESULTS
In the physician-reported eCRF population (n = 2966), the mean annual direct medical cost was €4065 in ARM 1 (n = 1835) and €2935 in ARM 2 (n = 1131). In the PPIE population (ARM 1, n = 1001; ARM 2, n = 647), mean annual direct cost was €4526 in ARM 1 and €3057 in ARM 2, mean annual direct non-medical cost was €1162 in ARM 1 and €1002 in ARM 2, mean annual indirect cost was €3098 in ARM 1 and €2309 ARM 2, and mean annual total cost was in €8787 in ARM 1 and €6368 in ARM 2. HRQoL scores showed moderate to high burden of UC in both groups.
CONCLUSIONS
CONCLUSIONS
The cost and HRQoL burden were high in patients in both ARM 1 and ARM 2 indicating unmet needs in the UC active population.
Identifiants
pubmed: 34863112
doi: 10.1186/s12876-021-02028-5
pii: 10.1186/s12876-021-02028-5
pmc: PMC8645093
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
456Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Therap Adv Gastroenterol. 2018 Dec 06;11:1756284818816956
pubmed: 30574193
Clin Gastroenterol Hepatol. 2017 Mar;15(3):385-392.e2
pubmed: 27645518
Dis Colon Rectum. 1998 Jan;41(1):33-40
pubmed: 9510308
Monaldi Arch Chest Dis. 2012 Sep;78(3):155-9
pubmed: 23614330
Gut. 1996 Nov;39(5):690-7
pubmed: 9014768
Inflamm Bowel Dis. 2005 Feb;11(2):171-7
pubmed: 15677911
Clin Exp Gastroenterol. 2015 Jul 17;8:197-204
pubmed: 26213474
J Crohns Colitis. 2016 Mar;10(3):239-54
pubmed: 26614685
Digestion. 2011;84(1):12-21
pubmed: 21304240
Am J Gastroenterol. 2003 May;98(5):1064-72
pubmed: 12809829
Mayo Clin Proc. 2014 Nov;89(11):1553-63
pubmed: 25199861
Gut. 2017 Apr;66(4):588-596
pubmed: 26646934
Gut. 2018 Feb;67(2):244-254
pubmed: 27780886
J Crohns Colitis. 2016 Apr;10(4):503
pubmed: 26619892
Inflamm Bowel Dis. 2013 Aug;19(9):1858-66
pubmed: 23660997
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Gastroenterology. 2006 Sep;131(3):719-28
pubmed: 16952541
Gut. 1992 Jul;33(7):938-41
pubmed: 1644333
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
Eur J Gastroenterol Hepatol. 2013 Jul;25(7):790-7
pubmed: 23571609
Aliment Pharmacol Ther. 2000 Dec;14(12):1553-9
pubmed: 11121902
Eur J Health Econ. 2011 Jun;12(3):273-83
pubmed: 20967482
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):253-66
pubmed: 25656310
Inflamm Bowel Dis. 2006 May;12(5):402-12
pubmed: 16670530
Gastrointest Endosc. 2017 Dec;86(6):1012-1014
pubmed: 29146080
Support Care Cancer. 2013 Jun;21(6):1525-50
pubmed: 23314601
World J Gastroenterol. 2014 Jul 28;20(28):9458-67
pubmed: 25071340
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
Aliment Pharmacol Ther. 2010 Apr;31(7):693-707
pubmed: 20064142
Gut. 2014 Jan;63(1):72-9
pubmed: 23135759
Clin Med (Lond). 2017 Oct;17(5):429-433
pubmed: 28974592
Inflamm Bowel Dis. 2012 Jul;18(7):1356-63
pubmed: 22162423
Inflamm Bowel Dis. 2018 Apr 23;24(5):966-976
pubmed: 29688466
Gut. 2014 Jul;63(7):1092-102
pubmed: 24107590
Gut. 1964 Feb;5:1-22
pubmed: 14127503